ASCENTAGE PHARMA GROUP INTERNATIONAL
Business
Ascentage Pharma Group International is a global, commercial-stage biopharmaceutical company engaged in discovery, development, and commercialization of novel cancer therapies. The company's lead assets are Olverembatinib, a third-generation tyrosine kinase inhibitor approved in China for chronic myeloid leukemia with global Phase 3 trials underway, and Lisaftoclax, a Bcl-2 inhibitor approved in China for chronic lymphocytic leukemia with multiple registrational trials globally. The pipeline includes additional clinical-stage candidates targeting hematological malignancies and solid tumors.
Summary from 20-F filed 2026-04-29
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-177.75M |
| Total assets | — |
| Total liabilities | $375.99M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ASCENTAGE PHARMA GROUP INTERNATIONAL's CIK number?
ASCENTAGE PHARMA GROUP INTERNATIONAL's SEC CIK number is 0002023311 (2023311). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ASCENTAGE PHARMA GROUP INTERNATIONAL's SEC filings?
All of ASCENTAGE PHARMA GROUP INTERNATIONAL's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.